49 results about "Scorpion toxin" patented technology

HIV envelope immunogens that display multivalent epitopes are provided. The immunogens are aggregated, “webbed” HIV envelope immunogens in which native envelope structures are stabilized due to interactions with multimeric derivatives of M9 scorpion toxin.

The invention discloses a purifying and refolding method for a scorpion toxin protein inclusion body. The method mainly comprises: expressing a scorpion toxin protein by virtue of recombinant escherichia coli, wherein the terminal C of the scorpion toxin protein contains His-tag; then opening a disulfide bond in the scorpion toxin protein by using a denaturation buffer solution; purifying the denatured scorpion toxin protein by virtue of a histidine affinity column; and then performing renaturation on the scorpion toxin protein by using a renaturation buffer solution, wherein the renaturation buffer solution comprises 50-200 mmol / L Na2HPO4, 10-100 mmol / L Tris, 0.1-1 mol / L L-Arg, 1-5 mmol / L EDTA, 0.1-5 mmol / L GSH, 0.05-0.5 mmol / L GSSG, 5-20% (v / v) of glycerinum and 0.01-5% (v / v) of tritonX-100, and the pH is 7-9. The scorpion toxin protein is prepared by the method disclosed by the invention, and the method has the advantages of being simple to operate and good in renaturation effects.

Provided are optimized polynucleotide sequences encoding a scorpion Androctonus australis neurotoxin AaIT, which are suitable for being transcribed and expressed in fungi. Also provided are the fungi capable of expressing AaIT, such as Metarhizium anisopliae, which have improved insecticidal efficiency and can be used for insect control in effect.

The invention discloses a scorpion toxin active polypeptide HsTx1 capable of improving cerebral ischemia and hypoxia, and a preparation method and application thereof. The amino acid sequence of the scorpion toxin active polypeptide HsTx1 with improving cerebral ischemia and hypoxia is AGKKERAGSRRTKIVMLKCIREHGH. The tropical rainforest scorpion toxin polypeptide HsTx1 purified by the present invention shows strong anti-cerebral ischemia and hypoxia (MCAO) activities and improves motor dysfunction in the cerebral ischemia and hypoxia model (MCAO) experiment, indicating that the "scorpion toxin of the present invention can improve cerebral ischemia and hypoxia." Hypoxic active polypeptide HsTx1" has great medical application prospects. The scorpion toxin active polypeptide HsTx1 with improving cerebral ischemia and hypoxia described in the present invention has the beneficial characteristics of strong activity of effectively improving cerebral ischemia hypoxia and motor dysfunction.

The invention discloses scorpion toxin antiviral polypeptide and a use of the same. Scorpion toxin antivirotic polypeptide (AVP-W1) is obtained through a molecular biological and chemical synthesis method, and then the antiviral activity of the AVP-W1 on measles virus (MeV) and human immunodeficiency virus (HIV) is measured through adopting an antibody neutralization method; moreover, the measurement shows that the AVP-W1 can effectively inhibit virus infection at a low concentration. The AVP-W1 has a tremendous prospect in making applied medicine which can cure or prevent a disease caused byvirus. Moreover, the antiviral peptide of the invention has high activity on MeV and HIV and a simple method, and can be developed as antiviral medicine.

The invention relates to a medicinal liquor containing scorpion or scorpion venom and yam, wherein, the scorpion wine is processed from corn wine through adopting raw materials according to the following weight proportion: 1 to 10 portions of scorpion (or 0.002 to 0.01 portion of scorpion venom), 0.4 to 4 portions of yam, 0.4 to 4 portions of aweto, 2 to 20 portions of Chinese date, 4 to 40 portions of medlar, 0.8 to 8 portions of red sage root, 0.6 to 6 portions of fleece-flower root and 4 to 40 portions of honey. The method includes the following steps: (1) alive scorpions are immersed in corn wine of 4 to 5 times weight for 12 hours to 360 hours at 10 DEG C to 60 DEG C to obtain scorpion venom wine macerate liquid; (2) yam, aweto, Chinese date, medlar, red sage root and fleece-flower root are immersed in corn wine of 8 times to 10 times weight for 12 hours to 720 hours at 10 DEG C to 80 DEG C to obtain wine macerate liquid; (3) both wine macerate liquids are combined with proportioning honey added to be blended into low alcohol wine or high alcohol wine which undergoes split charging, examination and warehousing. Keeping regular drinking of the scorpion wine can improve immunity of human bodyto increase disease resistance and prevent disease.

The invention discloses a method for producing recombinant scorpion toxin protein by adopting a silkworm as a parasitifer, which mainly comprises the following steps: adopting a scorpion cDNA as a template, adopting 5'-ACGTAGATCTATGGATGGATATATAAG-3' containing BglII enzyme cutting site as a forward primer and adopting 5'-ACGTAGATCT TTACTTTTTTCCAC-3' containing the BglII enzyme cutting site as a reverse primer to carry out PCR gene amplification reaction in 32 cycles to obtain a scorpion toxin gene; digesting pCR2.1-scorpion toxin by restriction endonuclease BglII to obtain a scorpion toxin gene fragment; cloning the scorpion toxin gene fragment in a baculovirus transfer vector pAcGP67b to obtain a recombinant pAcGP67b-scorpion toxin gene, carrying out homologous recombination with baculovirus BmNPV DNA of a silkworm in an insect cell by cotransfection to produce a recombinant virus; expressing in a silkworm body and purifying the recombinant scorpion toxin. Most of the recombinant scorpion toxin protein expressed by a silkworm larva is retained in a fat body of the silkworm; the scorpion toxin is purified from the fat body by an affinity chromatography; and the recombinant scorpion toxin has obvious biological toxicity, is suitable for the requirement of a biopharmaceutical industrialization level and has wide application prospect in the field of future medical and clinic treatment.

The invention relates to toxin peptides capable of selectively inhibiting a Kv1.3 potassium channel protein. The toxin peptides of the invention are modified anuroctonus scorpion toxin peptides.

The invention belongs to the field of medical biology, and particularly relates to a production method for recombining scorpion toxin protein AGAP. The method comprises the following steps: firstly, obtaining SUMO-AGAP fusion genes with His6 labels by using overlapping PCR technology; secondly, constructing a recombinant expression vector containing the SUMO-AGAP fusion genes; thirdly, transferring the constructed expression vector to a host cell to express; and finally, cracking the cell by using a physical method or a chemical agent, extracting recombinant fusion protein and His purified fusion protein to obtain pure SUMO-AGAP fusion protein, carrying out enzyme cutting reaction, releasing AGAP, and further purifying the fusion protein to obtain the purified AGAP protein. The method greatly improves the yield, saves the cost, and is simple and convenient to operate; and the AGAP produced by the method has broad biologic activity, can restrain the proliferation of various tumor cells, and simultaneously has analgesia effect.